Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.

Transcriptase Inhibitors: Lessons from the Development of Seven Representative Paradigms Dongyue Li,† Peng Zhan,† Erik De Clercq,‡ and Xinyong Liu*,† †Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012, Jinan, Shandong, P. R. China ‡Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium

[1]  F. Belardelli,et al.  Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation , 2003, AIDS.

[2]  Peng Zhan,et al.  HIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design , 2013, Medicinal research reviews.

[3]  A. Rieger,et al.  Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naïve Subjects , 2010, Antimicrobial Agents and Chemotherapy.

[4]  W. Schäfer,et al.  Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations. , 1993, Journal of medicinal chemistry.

[5]  D I Stuart,et al.  Binding of the Second Generation Non-nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding* , 2000, The Journal of Biological Chemistry.

[6]  David I Stuart,et al.  Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. , 2004, Journal of medicinal chemistry.

[7]  E. LaVoie,et al.  Bioisosterism: A Rational Approach in Drug Design. , 1996, Chemical reviews.

[8]  Bart De Corte,et al.  From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2005 .

[9]  Roderick E Hubbard,et al.  Fragment-based ligand discovery. , 2009, Molecular interventions.

[10]  E. De Clercq,et al.  Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV. , 2010, Bioorganic & Medicinal Chemistry.

[11]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. , 2001, Bioorganic & medicinal chemistry letters.

[12]  P. Metrangolo,et al.  Halogen bonding: a paradigm in supramolecular chemistry. , 2001, Chemistry.

[13]  C. Pannecouque,et al.  Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors. , 2010, Bioorganic & medicinal chemistry.

[14]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. , 2001, Bioorganic & medicinal chemistry letters.

[15]  S. Sarafianos,et al.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase , 2010, Viruses.

[16]  A. D. Clark,et al.  Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. , 1996, Structure.

[17]  L. Boone,et al.  Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. , 2004, Journal of medicinal chemistry.

[18]  Xianfeng Lin,et al.  Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses. , 2010, Bioorganic & medicinal chemistry letters.

[19]  Hongyu Zhao,et al.  Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. , 2007, Drug discovery today.

[20]  Xiaohong Liu,et al.  Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. , 2010, Journal of medicinal chemistry.

[21]  H. Stellbrink.  Antiviral drugs in the treatment of AIDS: what is in the pipeline ? , 2007, European journal of medical research.

[22]  C. Pannecouque,et al.  Lead Optimization of Diarylpyrimidines as Non‐nucleoside Inhibitors of HIV‐1 Reverse Transcriptase , 2010, ChemMedChem.

[23]  G. McGaughey,et al.  The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations. , 2008, Bioorganic & medicinal chemistry letters.

[24]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[25]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU). , 2001, Bioorganic & medicinal chemistry letters.

[26]  J. Tronchet,et al.  Nonnucleoside inhibitors of HIV-1 reverse transcriptase: from the biology of reverse transcription to molecular design. , 2003, Current topics in medicinal chemistry.

[27]  H. M. Vinkers,et al.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.

[28]  R. Pauwels,et al.  Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Frank Goebel,et al.  Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjects , 2006, AIDS.

[30]  Eric Westhof,et al.  Halogen bonds in biological molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[31]  F. Fleming,et al.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. , 2010, Journal of medicinal chemistry.

[32]  C. Mowbray.  Pyrazole NNRTIs 4: Selection of UK‐453,061 (Lersivirine) as a Development Candidate. , 2010 .

[33]  E. De Clercq,et al.  Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy. , 2010, Bioorganic & medicinal chemistry.

[34]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[35]  D. Green,et al.  Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase. , 1995, Journal of medicinal chemistry.

[36]  Nathan Brown,et al.  On scaffolds and hopping in medicinal chemistry. , 2006, Mini reviews in medicinal chemistry.

[37]  P. Fernandes,et al.  The Current Status of the NNRTI Family of Antiretrovirals Used Against HIV Infection , 2008 .

[38]  R. Hamatake,et al.  A Novel Nonnucleoside Analogue That Inhibits Human Immunodeficiency Virus Type 1 Isolates Resistant to Current Nonnucleoside Reverse Transcriptase Inhibitors , 2006, Antimicrobial Agents and Chemotherapy.

[39]  G. McGaughey,et al.  Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. , 2008, Journal of medicinal chemistry.

[40]  L. Boone,et al.  Antiviral Activity of GW678248, a Novel Benzophenone Nonnucleoside Reverse Transcriptase Inhibitor , 2005, Antimicrobial Agents and Chemotherapy.

[41]  Anthony C Legon,et al.  The halogen bond: an interim perspective. , 2010, Physical chemistry chemical physics : PCCP.

[42]  Omar Haq,et al.  Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures. , 2009, Journal of medicinal chemistry.

[43]  Hongyu Zhao,et al.  Medicinal chemistry strategies in follow-on drug discovery. , 2009, Drug discovery today.

[44]  Jan Balzarini,et al.  The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations. , 2005, Journal of the American Chemical Society.

[45]  A. Wood,et al.  Pyrazole NNRTIs 1: design and initial optimisation of a novel template. , 2009, Bioorganic & medicinal chemistry letters.

[46]  E. Barreiro,et al.  Molecular hybridization: a useful tool in the design of new drug prototypes. , 2007, Current medicinal chemistry.

[47]  Julian Tirado-Rives,et al.  Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. , 2003, Journal of the American Chemical Society.

[48]  Catherine Burt,et al.  Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays. , 2009, Journal of medicinal chemistry.

[49]  M. Allan,et al.  Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. , 2006, Bioorganic & medicinal chemistry letters.

[50]  From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2005, Journal of medicinal chemistry.

[51]  Michael Rowley,et al.  Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant. , 2006, Bioorganic & medicinal chemistry letters.

[52]  A. Wood,et al.  Pyrazole NNRTIs 3: optimisation of physicochemical properties. , 2009, Bioorganic & medicinal chemistry letters.

[53]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[54]  Hong Lu,et al.  Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[55]  Z. Sweeney,et al.  Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data. , 2008, Current opinion in drug discovery & development.

[56]  David A. Price,et al.  Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. , 2009, Bioorganic & medicinal chemistry letters.

[57]  P. Fernandes,et al.  The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. , 2008, Current medicinal chemistry.

[58]  R. Pauwels,et al.  Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity. , 2005, Journal of medicinal chemistry.

[59]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[60]  D. Stammers,et al.  Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. , 2006, Journal of medicinal chemistry.

[61]  W. Greenlee,et al.  5‐Chloro‐3‐(phenylsulfonyl)indole‐2‐carboxamide: A Novel, Non‐ Nucleoside Inhibitor of HIV‐1 Reverse Transcriptase. , 1994 .

[62]  Marcela Madrid,et al.  Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase. , 2005, Journal of the American Chemical Society.

[63]  M. Pfaller.  Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) , 2010 .

[64]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 1: From α-Anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU) , 2001 .

[65]  Erik De Clercq,et al.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.

[66]  Henri Moereels,et al.  Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors , 1995, Nature Structural Biology.

[67]  S. Sarafianos,et al.  Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. , 2009, Journal of molecular biology.

[68]  E. Seminari,et al.  Etravirine for the treatment of HIV infection , 2008, Expert review of anti-infective therapy.

[69]  Stephen H Hughes,et al.  In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). , 2005, Journal of medicinal chemistry.

[70]  R. Giridhar,et al.  The search for potent, small molecule NNRTIs: A review. , 2009, Bioorganic & medicinal chemistry.

[71]  Hong Lu,et al.  Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2010, Journal of medicinal chemistry.